Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thanks Sequester: FDA’s Human Drug Review Costs Decrease To Pre-FY 2011 Level

Executive Summary

The agency says human drug review costs were less than $1 billion in fiscal year 2013, the first time that’s happened since FY 2010.

You may also be interested in...



FDA Budget Issues Creep Into Strategic Priorities

“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says.

FDA Strains Under New NDA Review Model; Will Industry Want To Retain It?

Scheduling mid- and late-cycle meetings complicates reviews for FDA, but the fate of the “Program” probably depends on whether industry feels the extra two months produces better outcomes.

Sequester Travel: Halved FDA Budget Limits Opportunities For Scientists, Impacts Senior Officials Too

Analysis of meetings in FDA’s public calendar indicates Commissioner Hamburg, other senior leaders continue to attend meetings throughout the U.S. and overseas; stakeholders worry sequester-induced travel cuts prevent rank-and-file scientists from attending helpful events.

Related Content

Topics

UsernamePublicRestriction

Register

PS056300

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel